AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,540.50GBp
7:55am EDT
Price Change (% chg)

40.50p (+0.90%)
Prev Close
4,500.00p
Open
4,550.00p
Day's High
4,600.00p
Day's Low
4,519.50p
Volume
891,507
Avg. Vol
2,624,446
52-wk High
4,946.41p
52-wk Low
3,237.50p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.38
Market Cap (Mil.): £56,862.92
Shares Outstanding (Mil.): 1,262.75
Dividend: 53.10
Yield (%): 3.78

Financials

  AZN.L Industry Sector
P/E (TTM): 44.88 33.49 34.41
EPS (TTM): 1.00 -- --
ROI: 5.03 18.10 17.37
ROE: 8.94 18.76 18.18
Search Stocks

AstraZeneca wins U.S. approval for two-in-one diabetes pill

LONDON - A new two-in-one diabetes pill from AstraZeneca has been approved by U.S. regulators, the British drugmaker said on Thursday.

30 Oct 2014

AstraZeneca wins U.S. approval for two-in-one diabetes pill

LONDON, Oct 30 - A new two-in-one diabetes pill from AstraZeneca has been approved by U.S. regulators, the British drugmaker said on Thursday.

30 Oct 2014

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic: CEO

MUMBAI - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

Indian drugmaker Ranbaxy still has exclusive rights for Nexium generic -CEO

MUMBAI, Oct 28 - Indian drugmaker Ranbaxy Laboratories still has exclusive rights to the launch of AstraZeneca's heartburn drug Nexium in the United States, it said on Tuesday, despite regulatory concern over the manufacturing process.

28 Oct 2014

BUSINESS-NEWS-SCHEDULE AT 1330 GMT /9.30 AM ET

Editor: Malcolm Davidson +44 20 7542 6958

28 Oct 2014

Pfizer beats sales and profit forecasts, mum on future deals

- Pfizer Inc reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts to buy rival British drugmaker AstraZeneca Plc .

28 Oct 2014

UPDATE 2-Pfizer beats sales and profit forecasts, mum on future deals

(Adds CEO, analyst comment, looming patent expirations, shares)

28 Oct 2014

Pfizer beats Q3 forecasts, mum on likely future deals

Oct 28 - Pfizer Inc reported better than expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans in the wake of its recent failed efforts to buy rival British drugmaker AstraZeneca Plc.

28 Oct 2014

UPDATE 2-Bristol-Myers tops 3rd-qtr estimates as sales of top drugs sizzle

(Adds analyst comment, details on Opdivo cancer drug, shares)

24 Oct 2014

AstraZeneca cancer drug pipeline gets boost from European green light

LONDON - AstraZeneca's cancer drug pipeline received a boost on Friday, as European regulators recommended approval of an experimental medicine against ovarian cancer.

24 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks